Department of Gynecology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Acta Obstet Gynecol Scand. 2019 Jan;98(1):34-43. doi: 10.1111/aogs.13453. Epub 2018 Oct 26.
The objective of this study was to determine the impact of intra-abdominal residual disease size, type (carcinomatosis, tumor mass or both), and location (upper/lower abdominal/both) on overall survival in women with Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IIIC vs stage IV epithelial ovarian cancer who underwent primary debulking surgery.
Altogether 2092 women diagnosed with advanced epithelial ovarian cancer undergoing primary debulking surgery in Denmark during 2005-2016 were identified in the Danish Gynecological Cancer Database. The impact of residual disease size, type, and location were evaluated using univariate and multivariate analyses.
Complete cytoreduction (residual disease = 0) was achieved in 47.3% and 38.4% of women with stage IIIB-IIIC and IV epithelial ovarian cancer, respectively. A benefit in overall survival was observed in women with residual disease = 0 compared with women with residual disease, and among women with residual disease ≤1 cm compared with residual disease >2 cm in both stages IIIB-IIIC and stage IV in multivariate analyses. Multivariate analyses showed an inferior overall survival for women with both residual carcinomatosis and residual tumor mass compared with those with residual tumor mass or residual carcinomatosis only for stage IIIB-IIIC and IV, and an inferior overall survival for women with residual disease located in both the upper and lower abdomen compared with residual disease in the upper abdomen only in stages IIIB-IIIC.
Our results confirm the positive prognostic impact of both complete cytoreduction and residual disease ≤1 cm in stages IIIB-IIIC as well as stage IV epithelial ovarian cancer. Women with stage IV do benefit from cytoreductive surgery and should be considered for primary debulking surgery, if residual disease = 0 can initially be expected.
本研究的目的是确定在接受初次肿瘤细胞减灭术的FIGO 分期为 IIIB 期-IIIIC 期和 IV 期上皮性卵巢癌患者中,腹腔内残余疾病大小、类型(癌性播散、肿瘤团块或两者兼有)和部位(上腹部/下腹部/两者均有)对总体生存的影响。
在丹麦妇科癌症数据库中,共确定了 2092 名在 2005 年至 2016 年期间接受初次肿瘤细胞减灭术治疗的晚期上皮性卵巢癌患者。使用单变量和多变量分析评估残余疾病大小、类型和部位的影响。
完全肿瘤细胞减灭术(残余疾病=0)在 IIIB 期-IIIIC 期和 IV 期上皮性卵巢癌患者中分别达到 47.3%和 38.4%。在多变量分析中,与残余疾病患者相比,残余疾病=0 的患者以及残余疾病≤1cm 的患者在 IIIB 期-IIIIC 期和 IV 期均有更好的总体生存获益。多变量分析显示,与仅患有肿瘤团块或癌性播散的患者相比,IIIb 期-IIIIC 期和 IV 期同时患有残余癌性播散和残余肿瘤团块的患者总体生存更差,与仅上腹部有残余疾病的患者相比,IIIb 期-IIIIC 期下腹部和上腹部均有残余疾病的患者总体生存更差。
我们的研究结果证实了在 IIIB 期-IIIIC 期以及 IV 期上皮性卵巢癌中,完全肿瘤细胞减灭术和残余疾病≤1cm 均有积极的预后影响。IV 期患者确实受益于肿瘤细胞减灭术,如果最初可以预期残余疾病=0,则应考虑进行初次肿瘤细胞减灭术。